ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Tidal Investments LLC

Tidal Investments LLC trimmed its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 46.8% in the third quarter, HoldingsChannel reports. The firm owned 38,334 shares of the biotechnology company’s stock after selling 33,710 shares during the period. Tidal Investments LLC’s holdings in ADMA Biologics were worth $766,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. USA Financial Formulas grew its holdings in ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 539 shares during the last quarter. Vontobel Holding Ltd. lifted its position in shares of ADMA Biologics by 7.0% in the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 888 shares in the last quarter. Hollencrest Capital Management acquired a new stake in shares of ADMA Biologics during the third quarter valued at $30,000. Mirae Asset Global Investments Co. Ltd. increased its position in ADMA Biologics by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 1,509 shares in the last quarter. Finally, Larson Financial Group LLC acquired a new position in ADMA Biologics in the 3rd quarter valued at about $31,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Down 2.8 %

ADMA opened at $17.40 on Friday. The stock has a market capitalization of $4.11 billion, a price-to-earnings ratio of 62.14 and a beta of 0.70. ADMA Biologics, Inc. has a 12 month low of $4.07 and a 12 month high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The business has a 50-day moving average of $18.92 and a two-hundred day moving average of $16.30.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the previous year, the firm earned $0.01 earnings per share. On average, research analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ADMA shares. HC Wainwright raised their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James boosted their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.